Growth hormone
secretagogue research.
These are among the most studied and most misrepresented compounds in the category. We will not narrate outcomes for you. We will tell you precisely what they are and what the published work investigates. Compounds studied in laboratory and animal models of the somatotropic axis: ghrelin-receptor agonists, GHRH-receptor agonists, and modified GH-releasing peptides. Research-grade Cresten compounds with batch-specific COA verification.
Growth hormone secretagogue research.
The growth hormone secretagogue research category covers compounds studied in laboratory and animal models for their effects on the somatotropic axis: ghrelin-receptor binding (GHSR1a), pulsatile growth hormone release from the anterior pituitary, growth hormone-releasing hormone (GHRH) receptor activation, and downstream IGF-1 signalling. The compounds in this category were originally identified during research into the molecular regulation of GH release and have remained important laboratory tools for studying somatotropic axis biology.
Research peptides in this category are studied for receptor selectivity (some compounds activate ACTH and cortisol pathways, others do not), for in-vivo dose-response on serum GH and IGF-1 in animal models, and for their effects on downstream tissues including muscle, adipose, and bone in preclinical research.
Cresten compounds studied in this area.
Ipamorelin
CAS 170851-70-4Synthetic pentapeptide derived from GHRP-1. Studied for selective GH-releasing activity via the GHSR1a receptor without significant cortisol or ACTH elevation. Notable for its receptor selectivity in published research.
CJC-1295 No DAC
CAS 863288-34-0Modified analog of GHRH (1-29) without the drug-affinity-complex (DAC) modification. Truncated GHRH analog with extended half-life relative to native GHRH. Studied in laboratory models of GHRH-receptor activation.
Mechanism and receptor pharmacology.
The two compounds above act on different receptors in the somatotropic axis. Ipamorelin is a GHSR1a (ghrelin receptor) agonist; CJC-1295 No DAC is a GHRH receptor agonist. Published research has examined whether the two compounds’ effects on GH release are synergistic in animal models given the different receptor mechanisms.
For laboratory research, the distinction matters: assays designed to measure ghrelin-receptor activation should use ipamorelin or related GHSR1a-active compounds; assays of GHRH-receptor pharmacology should use CJC-1295 No DAC or related GHRH analogs.
Research literature indexed on this area.
Methodology and verification.
Synthetic peptides in the somatotropic-axis research category are particularly sensitive to identity confirmation: compounds with similar names (CJC-1295 with DAC, CJC-1295 without DAC, sermorelin, tesamorelin) have different sequences and different pharmacology. Cresten Labs publishes the LC-MS spectrum on every batch certificate to confirm exact identity. The current batch certificate is published on the relevant compound’s product page.